-+ 0.00%
-+ 0.00%
-+ 0.00%

Cosmo Pharmaceuticals' H1 Loss Widens; Revenue Down

MT Newswires·07/23/2026 01:35:14
Listen to the news
01:35 AM EDT, 07/23/2026 (MT Newswires) -- Cosmo Pharmaceuticals (COPN.SW) said Thursday that its loss for the first half widened, while revenue decreased year over year. Loss attributable to owners for the six months ended June 30 was 4.8 million euros, compared with 2 million euros a year ago. Loss per share moved to 0.279 euro from 0.126 euro. The pharmaceutical company's revenue was 50.2 million euros, compared with 51.7 million euros a year ago. For full-year 2026, the company affirmed its guidance for total revenue of between 105 million euros and 110 million euros.